Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II clinical trial assessing QEL-005 in patients with Rheumatoid Arthritis and Systemic Sclerosis

Next Previous
Trial Profile

Phase I/II clinical trial assessing QEL-005 in patients with Rheumatoid Arthritis and Systemic Sclerosis

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QEL-005 (Primary)
  • Indications Rheumatoid arthritis; Systemic scleroderma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CHILL

Most Recent Events

  • 03 Mar 2026 According to Quell Therapeutics media release, advancement of the QEL-005 program into clinical development follows the recent approval by UK MHRA (Medicines and Healthcare products Regulatory Agency) of the company's Clinical Trial Application (CTA).
  • 03 Mar 2026 According to Quell Therapeutics media release, the company will recruit participants in the UK, Germany and Spain, with patient enrolment underway at leading clinical centres across the UK. Early clinical findings are expected during Q1 2027.
  • 03 Mar 2026 Status changed from planning to recruiting, according to a Quell Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top